Telix Pharmaceuticals has selected Cardinal Health as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET1 agent, Zircaix for the imaging of kidney cancer in the United States subject to regulatory approval. In preparation for a planned commercial rollout, Telix has contracted with Cardinal Health to enable Zircaix availability across a wide range of U.S. locations. Commencement of the distribution agreement between Telix and Cardinal Health is subject to regulatory approval and includes industry-standard commercial performance and termination conditions.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLPPF: